Alimera Competitors

Delisted . USA . 
Stock . Alimera Sciences
ALIMDelisted Stock  USD 5.54  0.01  0.18%   
Alimera Sciences competes with Shuttle Pharmaceuticals, Lifecore Biomedical, Journey Medical, Organogenesis Holdings, and Cyclo Therapeutics; as well as few others. The company conducts business under Pharmaceuticals sector and is part of Health Care industry. Analyzing Alimera Sciences competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Alimera Sciences to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Alimera Sciences competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
2.875.548.21
Details
Intrinsic
Valuation
LowRealHigh
1.524.196.86
Details

Alimera Sciences Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Alimera Sciences and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Alimera and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Alimera Sciences does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
ADMP
+ 0.98
LSDI
ATNX
+ 0.94
LSDI
ATNX
+ 0.94
ADMP
ATNX
+ 0.88
MNK
ADMP
+ 0.84
MNK
ADMP
+ 0.81
SHPH
  
High negative correlations   
MMNFF
- 0.94
ADMP
MMNFF
- 0.94
LSDI
MMNFF
- 0.88
ATNX
MMNFF
- 0.8
MNK
LSDI
- 0.73
DERM
ADMP
- 0.72
DERM

Risk-Adjusted Indicators

There is a big difference between Alimera Stock performing well and Alimera Sciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Alimera Sciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
SHPH  5.63 (1.03) 0.00  17.64  0.00 
 0.00 
 10.08 
(13.02)
 50.96 
LFCR  4.14  0.38  0.06  0.38  6.50 
(4.14)
 9.76 
(6.68)
 30.90 
MNK  16.59  1.90  0.10 (0.64) 13.99 
(33.75)
 12.50 
(30.95)
 504.19 
DERM  3.17  0.17  0.05  0.24  3.81 
(3.52)
 7.30 
(6.06)
 22.80 
LSDI  298.43  147.97  3.23  5.56  27.98 
(972.40)
 550.00 
(81.82)
 3,998 
ADMP  4.75 (1.86) 0.00 (2.69) 0.00 
 0.00 
 8.72 
(11.60)
 40.76 
ORGO  3.16  0.37  0.15  0.26  3.22 
(3.66)
 7.55 
(5.54)
 37.89 
CYTH  3.52 (0.24) 0.00  5.93  0.00 
 0.00 
 5.33 
(5.19)
 25.00 
ATNX  13.35 (3.60) 0.00  1.39  0.00 
 0.00 
 25.00 
(35.00)
 143.13 
MMNFF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
All Fundamental Data

Alimera Sciences Competitive Analysis

The better you understand Alimera Sciences competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Alimera Sciences' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Alimera Sciences' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ALIM SHPH LFCR MNK DERM LSDI ADMP ORGO CYTH ATNX
 0.18 
 5.54 
Alimera
 1.15 
 0.86 
Shuttle
 2.05 
 7.46 
Lifecore
 4.17 
 0.46 
Mallinckrodt
 6.89 
 5.74 
Journey
 0.00 
 0.02 
Lucy
 12.12 
 1.74 
Adamis
 0.25 
 4.04 
Organogenesis
 6.85 
 0.68 
Cyclo
 0.00 
 0 
Athenex
Market Volatility
(90 Days Market Risk)
Slightly risky
Out of control
Slightly risky
Very steady
Moderately volatile
Very steady
Very steady
Risky
Dangerous
Very steady
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Solid
Very Weak
Insignificant
Very Weak
Very Weak
OK
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Very High
Below Average
Dangerous
Low
Dangerous
Dangerous
Low
Very High
Dangerous
Current Valuation
(Equity Enterprise Value)
Over Valued
Fairly Valued
Fairly Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Under Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Buy
Not Available
Strong Buy
Not Available
Not Available
Strong Buy
Buy
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Strong Sell
Not Rated
Strong Sell
Not Rated
Not Rated
Cautious Hold
Strong Sell
Not Rated
Current Ratio
1.3
0.03
N/A
2.98
1.4
N/A
1.58
2.62
2.93
1.31
Net Asset
153.52 M
5.95 M
273.7 M
6.01 B
76.85 M
8.78 M
10.93 M
460.02 M
13.25 M
204.06 M
Profit Margin
-0.15
N/A
0.0509
-0.83
-0.32
N/A
N/A
-0.0162
N/A
-1.01
EBITDA
7.28 M
(5.89 M)
812 K
(723.5 M)
1.92 M
(5.66 M)
(24.27 M)
36.03 M
(20.03 M)
(69.57 M)
Operating Margin
0.0786
N/A
-0.37
-0.0147
-0.2
-89.07
-3.74
0.0542
-45.78
-0.72
Current Valuation
360.44 M
3.6 M
400.55 M
2.62 B
109.54 M
2.04 M
7.28 M
550.26 M
32.28 M
82.22 M
Price To Book
7.77
4.16
15.35
0.069
10.27
0.43
8.62
1.93
59.1
1.08
Retained Earnings
(418.49 M)
(15.49 M)
(166.52 M)
(588.2 M)
(72.36 M)
(44.42 M)
(304.56 M)
(40.97 M)
(83.86 M)
(1.02 B)
Current Asset
51.6 M
N/A
N/A
1.51 B
217.23 M
N/A
4.15 M
24.47 M
N/A
129.03 M
Beta
1.25
0.74
0.94
3.06
0.92
N/A
1.28
1.6
-0.38
1.35
Number Of Employees
154
8
524
2.67 K
41
2
11
862
8
269
Shares Outstanding
54.38 M
3.66 M
36.83 M
13.29 M
14.89 M
1.76 M
9.36 M
132.58 M
28.77 M
8.7 M
Cash Flow From Operations
(14.26 M)
(5.58 M)
(217 K)
455.4 M
5.24 M
(4.27 M)
(25.9 M)
30.92 M
(16.19 M)
(75.01 M)
Total Debt
67.4 M
1.09 M
130.36 M
3.07 B
17.73 M
1.79 M
342.56 K
119.35 M
1.03 M
42.36 M
Return On Equity
-0.35
-1.86
0.17
-1.11
-1.3
N/A
-7.85
-0.0266
-226.64
-19.27
Z Score
N/A
N/A
N/A
0.09
N/A
N/A
-33.43
N/A
N/A
-7.51
Return On Asset
0.0098
-0.62
-0.0225
-0.0029
-0.17
-0.99
-1.04
0.0164
-2.82
-0.2
Number Of Shares Shorted
578.49 K
702.63 K
2.57 M
1.79 M
60.75 K
2.68 K
98.94 K
9.79 M
114.42 K
356.33 K
Book Value Per Share
0.74
2.02
-0.13
47.06
0.53
0.046
-4.24
2.1
0.17
-0.75
Current Liabilities
7.85 M
N/A
N/A
1.23 B
25.9 M
N/A
2.75 M
23.22 M
N/A
42.19 M
Total Asset
153.52 M
5.95 M
273.7 M
6.01 B
76.85 M
8.78 M
10.93 M
460.02 M
13.25 M
204.06 M
Short Ratio
1.93
0.25
19.6
0.19
0.71
N/A
0.02
23.59
3.82
5.24
Target Price
5.67
N/A
8.0
1.75
10.0
35.0
0.42
4.7
0.95
2.5
Debt To Equity
N/A
0.091
N/A
1.44
0.61
N/A
0.16
0.52
N/A
4.58
Shares Owned By Institutions
86.54
1.81
69.57
96.64
14.56
7.08
16.59
48.28
13.17
29.87
Market Capitalization
301.29 M
3.19 M
269.21 M
4.52 M
112.18 M
906.91 K
7.25 M
536.94 M
21 M
2.33 M
Price To Earning
1.65
N/A
N/A
1.09
-9.5
N/A
-6.21
17.12
N/A
-4.87
Price To Earnings To Growth
N/A
N/A
3.51
-0.01
-0.04
N/A
N/A
6.15
N/A
N/A
Price To Sales
3.02
N/A
2.1
0.0616
1.94
54.2
17.64
1.18
18.54
0.2
Net Income
(20.13 M)
(6.59 M)
9.33 M
(717.4 M)
(3.85 M)
(8.99 M)
(26.48 M)
4.95 M
(20.06 M)
(98.97 M)
Earnings Per Share
1.05
-4.25
0.13
-0.78
-0.92
-7.64
-10.14
-0.05
-0.9
-10.45
Shares Owned By Insiders
5.34
27.8
5.31
10.09
30.47
30.39
7.81
43.44
40.07
9.73
Revenue
80.75 M
N/A
128.26 M
2.21 B
79.18 M
7.05 K
4.76 M
433.14 M
1.08 M
102.82 M
Working Capital
30.51 M
4.55 M
42.16 M
1.29 B
14.59 M
1.11 M
(2.12 M)
144.53 M
3.85 M
10.05 M
Cash And Equivalents
7.86 M
50.44 K
N/A
1.34 B
38.14 M
N/A
8.88 M
113.24 M
4.29 M
23.33 M
Cash Per Share
1.12
N/A
N/A
26.93
2.17
N/A
0.06
0.87
0.51
0.19
Gross Profit
52 M
N/A
27.29 M
610 M
42.89 M
2.55 K
(1.43 M)
345.87 M
1.23 M
26.7 M
Day Typical Price
5.54
0.87
7.44
0.47
5.66
0.02
1.8
4.04
0.68
0.0022
Accumulation Distribution
0.0054
8191.04
10156.09
0.1
13388.71
N/A
0.16
44645.24
2619.54
N/A
Market Facilitation Index
0.03
0.0
0.0
0.05
0.0
N/A
0.32
N/A
0.0
N/A
Daily Balance Of Power
(0.33)
(0.12)
0.4545
(0.40)
0.7255
0.0
(0.75)
(0.05)
(1.25)
0.0
Period Momentum Indicator
(0.01)
(0.01)
0.15
(0.02)
0.37
N/A
(0.24)
(0.01)
(0.05)
N/A
Rate Of Daily Change
1.0
0.99
1.02
0.96
1.07
1.0
0.88
1.0
0.93
1.0
Day Median Price
5.55
0.88
7.43
0.48
5.63
0.02
1.83
4.04
0.68
0.0022
Price Action Indicator
(0.01)
(0.03)
0.11
(0.03)
0.3
N/A
(0.21)
N/A
(0.03)
N/A
Coefficient Of Variation
735.41
(804.94)
1075.29
3635.17
1188.78
471.09
(387.46)
710.9
(1,966)
(521.77)
Mean Deviation
2.74
5.63
4.14
16.59
3.17
298.43
4.75
3.16
3.52
13.35
Jensen Alpha
1.28
(1.03)
0.3835
1.9
0.1674
147.97
(1.86)
0.3726
(0.24)
(3.60)
Total Risk Alpha
(0.21)
(2.34)
(0.40)
(7.61)
(0.32)
39.03
(2.85)
(0.09)
(0.99)
(7.17)
Sortino Ratio
0.6372
N/A
0.0602
0.0968
0.0538
3.23
N/A
0.1529
N/A
N/A
Downside Variance
3.31
N/A
53.08
233.18
16.83
2194.39
N/A
13.96
N/A
N/A
Standard Deviation
9.49
8.26
6.12
58.48
4.18
712.57
6.84
4.99
4.7
20.52
Kurtosis
61.22
5.34
4.75
59.21
1.19
23.32
2.58
13.82
2.88
6.54
Potential Upside
3.28
10.08
9.76
12.5
7.3
550.0
8.72
7.55
5.33
25.0
Treynor Ratio
(57.68)
17.64
0.384
(0.64)
0.2368
5.56
(2.69)
0.2617
5.93
1.39
Maximum Drawdown
82.36
50.96
30.9
504.19
22.8
3997.5
40.76
37.89
25.0
143.13
Variance
90.08
68.17
37.5
3420.05
17.48
507759.06
46.82
24.9
22.11
421.01
Market Risk Adjusted Performance
(57.67)
17.65
0.394
(0.63)
0.2468
5.57
(2.68)
0.2717
5.94
1.4
Risk Adjusted Performance
0.1135
(0.09)
0.0801
0.031
0.0727
0.1728
(0.19)
0.1163
(0.03)
(0.14)
Skewness
7.69
0.9704
(1.13)
7.5
(0.36)
4.85
(0.68)
2.56
(0.28)
(1.52)
Semi Deviation
0.37
N/A
6.5
13.99
3.81
27.98
N/A
3.22
N/A
N/A
Information Ratio
0.1222
(0.14)
0.0716
0.0253
0.0528
0.2121
(0.28)
0.1145
(0.08)
(0.20)
Value At Risk
(0.72)
(13.02)
(6.68)
(30.95)
(6.06)
(81.82)
(11.60)
(5.54)
(5.19)
(35.00)
Expected Short fall
(4.03)
N/A
(4.14)
(33.75)
(3.52)
(972.40)
N/A
(3.66)
N/A
N/A
Downside Deviation
1.82
N/A
7.29
15.27
4.1
46.84
N/A
3.74
N/A
N/A
Semi Variance
0.1369
N/A
42.23
195.81
14.55
782.66
N/A
10.39
N/A
N/A

Alimera Sciences Competition Performance Charts

Five steps to successful analysis of Alimera Sciences Competition

Alimera Sciences' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Alimera Sciences in relation to its competition. Alimera Sciences' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Alimera Sciences in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Alimera Sciences' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Alimera Sciences, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Alimera Sciences position

In addition to having Alimera Sciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Semiconductor Thematic Idea Now

Semiconductor
Semiconductor Theme
Companies involved in production of semiconductor and semiconductor materials. The Semiconductor theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Semiconductor Theme or any other thematic opportunities.
View All  Next Launch
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in Alimera Stock

If you are still planning to invest in Alimera Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Alimera Sciences' history and understand the potential risks before investing.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY